Phase II clinical trials with rhizoxin in breast cancer and melanoma

British Journal of Cancer

Volumn 73, Issue 3, 1996, Pages 397-399

  Hanauske, A R ^a   Catimel, G ^b   Aamdal, S ^c   Ten Bokkel Huinink, W ^d   Paridaens, R ^e   Pavlidis, N ^f   Kaye, S B ^g   Te Velde, A ^h   Wanders, J ^h   Verweij, J ⁱ  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b CENTRE LÉON BÉRARD   (France)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f UNIVERSITY OF IOANNINA   (Greece)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

^h EORTC NDDO   (Netherlands)

ⁱ ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Breast cancer; Melanoma; Phase II trial; Rhizoxin

Indexed keywords

ANTINEOPLASTIC AGENT; RHIZOXIN;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; MELANOMA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA;

EID: 9044229142     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.68     Document Type: Article

References (15)

1. BAI RL, PETTIT GR AND HAMEL E. (1990). Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J. Biol. Chem., 265, 17141-17149.
2. BISSETT D, GRAHAM MA, SETANOIANS A, CHADWICK GA, WILSON P, KOIER I, HENRAR R, SCHWARTSMANN G, CASSIDY J, KAYE SB AND KERR DJ. (1992). Phase I and pharmacokinetic study of rhizoxin. Cancer Res., 53, 2894-2898.
3. GRAHAM MA, BISSETT D, SETANOIANS A, HAMILTON T, KERR DJ, HENRAR R AND KAYE SB. (1992). Preclinical and Phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme. J. Natl Cancer Inst., 84, 494-500.
4. HAMEL E. (1992). Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmacol. Ther., 55, 31-51.
5. HENDRIKS HR, PLOWMAN J, BERGER DP, PAULL KD, FIEBIG HH, FODSTAD O, DREEF VAN DER MEULEN HC, HENRAR RE, PINEDO HM AND SCHWARTSMANN G. (1992). Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent [see comments]. Ann. Oncol., 3, 755-763.
6. IWASAKI S, KOBAYASHI H, FURUKAWA J, NAMIKOSHI M, OKUDA S, SATO Z, MATSUDA I AND NODA T. (1984). Studies on macrocyclic lactone antibiotics. VII. Structure of a phytotoxin 'rhizoxin' produced by Rhizopus chinensis. J. Antibiot. Tokyo., 37, 354-362.
7. IWASAKI S, NAMIKOSHI M, KOBAYASHI H, FURUKAWA J, OKUDA S, ITAI A, KASUYA A, IITAKA Y AND SATO Z (1986). Studies on macrocyclic lactone antibiotics. VIII. Absolute structures of rhizoxin and a related compound. J. Antibiot. Tokyo., 39, 424-429.
8. KERR DJ, RUSTIN GJ, KAYE SB, SELBY P, BLEEHEN NM, HARPER P AND BRAMPTON MH. (1995). Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer. Br. J. Cancer, 72, 1267-1269.
9. KIYOTO S, KAWAI Y, KAWAKITA T, KINO E, OKUHARA M, UCHIDA I, TANAKA H, HASHIMOTO M, TERANO H, KOHSAKA M, AOKI M AND IMANAKA H. (1986). A new anti-tumour complex, WF-1360, WF-1360A, B, C, D, E and F. J. Antibiot. Tokyo., 39, 762-772.
10. OTAKE N. (1988). [The structure and antitumour activity of antitumour antibiotics - recent progress]. Gan. To. Kagaku. Ryoho., 15, 369-379.
11. TAKAHASHI M, IWASAKI S, KOBAYASHI H, OKUDA S, MURAI T AND SATO Y. (1987a). Rhizoxin binding to tubulin at the maytansine-binding site. Biochim. Biophys. Acta, 926, 215-223.
12. TAKAHASHI M, IWASAKI S, KOBAYASHI H, OKUDA S, MURAI T, SATO Y, HARAGUCHI HIRAOKA T AND NAGANO H. (1987b). Studies on macrocyclic lactone antibiotics. XI. Anti-mitotic and anti-tubulin activity of new anti-tumour antibiotics, rhizoxin and its homologues [published erratum appears in J Antibiot (Tokyo) 1987 Apr;40(4):following 565]. J. Antibiot. Tokyo., 40, 66-72.
13. TAKAHASHI M, KOBAYASHI H AND IWASAKI S. (1989). Rhizoxin resistant mutants with an altered beta-tubulin gene in Aspergillus nidulans. Mol. Gen. Genet., 220, 53-59.
14. TAKIGAWA N, OHNOSHI T, UEOKA H, HORIGUCHI T, KIURA K, TABATA M, SEGAWA Y, SHIBAYAMA T, GENBA K, MATSUMURA T. (1993). [Assessment of anti-tumour activity rhizoxin for human lung cancer cell lines: a potent new drug for drug-resistant lung cancer]. Gan. To. Kagaku. Ryoho., 20, 1221-1226.
15. TSURUO T, OH HARA T, IIDA H, TSUKAGOSHI S, SATO Z, MATSUDA I, IWASAKI S, OKUDA S, SHIMIZU F, SASAGAWA K, FUKAMI M, FUKUDA K AND ARAKAWA M. (1986). Rhizoxin, a macrocyclic lactone antibiotic, as a new anti-tumour agent against human and murine tumour cells and their vincristine-resistant sublines. Cancer Res., 46, 381-385.